中国血液净化 ›› 2023, Vol. 22 ›› Issue (02): 128-132.doi: 10.3969/j.issn.1671-4091.2023.02.011

• 综述 • 上一篇    下一篇

终末期肾病透析患者肌少症的发病机制及诊治进展

万 利    王 梅   

  1. 102202  北京,1北京大学国际医院肾脏内科血液净化中心
    100044  北京,2北京大学人民医院肾内科
  • 收稿日期:2022-09-29 修回日期:2022-11-16 出版日期:2023-02-12 发布日期:2023-02-12
  • 通讯作者: 王梅 E-mail:wangmei@pkuih.edu.cn

The pathogenesis and treatment of sarcopenia in end-stage renal disease patients on maintenance dialysis

WAN Li, WANG Mei   

  1. 1Blood Purification Center, Department of Nephrology, Peking University International Hospital, Beijing 102206, China; 2Department of Nephrology, Peking University People’s Hospital, Beijing 100044, China
  • Received:2022-09-29 Revised:2022-11-16 Online:2023-02-12 Published:2023-02-12
  • Contact: 100044 北京,2北京大学人民医院肾内科 E-mail:wangmei@pkuih.edu.cn

摘要: 肌少症是以骨骼肌质量、力量以及功能降低为主要特征的退行性综合征。终末期肾病透析患者由于疾病本身、各种并发症、透析治疗及其带来的活动减少等,可加速肌肉消耗,增加肌少症的发生。透析患者合并肌少症的发生率高,死亡率高,需要早期预防、早期诊断和治疗。现就透析患者肌少症的发病机制及诊治进展进行综述。

关键词: 终末期肾病, 透析, 肌少症, 发病机制, 诊疗

Abstract: Sarcopenia is a syndrome characterized by progressive and generalized loss of skeletal muscle mass, strength and function. End-stage renal disease (ESRD) patients are at a higher risk of accelerated muscle wasting due to the renal diseases itself, various complications, dialysis treatment and reduced activity from dialysis treatment. The incidence of sarcopenia is higher in dialysis patients and the mortality will be increased in dialysis patients with sarcopenia, highlighting the great importance of early prevention, detection and treatment of muscle wasting. In this article, we summarize the pathogenesis, diagnosis and treatment of sarcopenia in ESRD patients on maintenance dialysis.

Key words: nd stage renal disease, Dialysis, Sarcopenia, Pathogenesis, Diagnosis and treatment

中图分类号: